vs

Side-by-side financial comparison of AVITA Medical, Inc. (RCEL) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.

WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $17.6M, roughly 1.5× AVITA Medical, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -66.0%, a 105.2% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs -4.3%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 17.3%).

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.

RCEL vs WTBA — Head-to-Head

Bigger by revenue
WTBA
WTBA
1.5× larger
WTBA
$26.9M
$17.6M
RCEL
Growing faster (revenue YoY)
WTBA
WTBA
+20.9% gap
WTBA
16.6%
-4.3%
RCEL
Higher net margin
WTBA
WTBA
105.2% more per $
WTBA
39.2%
-66.0%
RCEL
More free cash flow
WTBA
WTBA
$18.5M more FCF
WTBA
$12.4M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
17.3%
WTBA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RCEL
RCEL
WTBA
WTBA
Revenue
$17.6M
$26.9M
Net Profit
$-11.6M
$10.6M
Gross Margin
81.2%
Operating Margin
-59.1%
50.0%
Net Margin
-66.0%
39.2%
Revenue YoY
-4.3%
16.6%
Net Profit YoY
-0.3%
34.8%
EPS (diluted)
$-0.37
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCEL
RCEL
WTBA
WTBA
Q1 26
$26.9M
Q4 25
$17.6M
$24.2M
Q3 25
$17.1M
$25.0M
Q2 25
$18.4M
$23.8M
Q1 25
$18.5M
$23.1M
Q4 24
$18.4M
$20.9M
Q3 24
$19.5M
$20.3M
Q2 24
$15.2M
$19.6M
Net Profit
RCEL
RCEL
WTBA
WTBA
Q1 26
$10.6M
Q4 25
$-11.6M
$7.4M
Q3 25
$-13.2M
$9.3M
Q2 25
$-9.9M
$8.0M
Q1 25
$-13.9M
$7.8M
Q4 24
$-11.6M
$7.1M
Q3 24
$-16.2M
$6.0M
Q2 24
$-15.4M
$5.2M
Gross Margin
RCEL
RCEL
WTBA
WTBA
Q1 26
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Operating Margin
RCEL
RCEL
WTBA
WTBA
Q1 26
50.0%
Q4 25
-59.1%
39.6%
Q3 25
-53.6%
45.8%
Q2 25
-60.5%
43.4%
Q1 25
-63.9%
43.4%
Q4 24
-54.1%
30.9%
Q3 24
-70.6%
36.6%
Q2 24
-102.8%
32.6%
Net Margin
RCEL
RCEL
WTBA
WTBA
Q1 26
39.2%
Q4 25
-66.0%
30.7%
Q3 25
-77.3%
37.3%
Q2 25
-53.9%
33.5%
Q1 25
-74.9%
34.0%
Q4 24
-63.0%
34.0%
Q3 24
-82.9%
29.3%
Q2 24
-101.3%
26.5%
EPS (diluted)
RCEL
RCEL
WTBA
WTBA
Q1 26
$0.61
Q4 25
$-0.37
$0.44
Q3 25
$-0.46
$0.55
Q2 25
$-0.38
$0.47
Q1 25
$-0.53
$0.46
Q4 24
$-0.44
$0.41
Q3 24
$-0.62
$0.35
Q2 24
$-0.60
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCEL
RCEL
WTBA
WTBA
Cash + ST InvestmentsLiquidity on hand
$18.2M
$362.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-16.6M
$270.7M
Total Assets
$56.4M
$4.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCEL
RCEL
WTBA
WTBA
Q1 26
$362.0M
Q4 25
$18.2M
$471.1M
Q3 25
$23.3M
$232.9M
Q2 25
$15.7M
$345.2M
Q1 25
$25.8M
Q4 24
$35.9M
$243.5M
Q3 24
$44.4M
Q2 24
$54.1M
Stockholders' Equity
RCEL
RCEL
WTBA
WTBA
Q1 26
$270.7M
Q4 25
$-16.6M
$266.0M
Q3 25
$-6.7M
$255.1M
Q2 25
$-12.9M
$240.9M
Q1 25
$-4.6M
$237.9M
Q4 24
$4.5M
$227.9M
Q3 24
$12.2M
$235.4M
Q2 24
$23.9M
$223.9M
Total Assets
RCEL
RCEL
WTBA
WTBA
Q1 26
$4.0B
Q4 25
$56.4M
$4.1B
Q3 25
$63.7M
$4.0B
Q2 25
$58.1M
$4.1B
Q1 25
$69.6M
$4.0B
Q4 24
$79.7M
$4.0B
Q3 24
$81.1M
$4.0B
Q2 24
$87.8M
$4.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCEL
RCEL
WTBA
WTBA
Operating Cash FlowLast quarter
$-5.4M
$12.9M
Free Cash FlowOCF − Capex
$-6.1M
$12.4M
FCF MarginFCF / Revenue
-34.7%
46.0%
Capex IntensityCapex / Revenue
3.8%
1.8%
Cash ConversionOCF / Net Profit
1.22×
TTM Free Cash FlowTrailing 4 quarters
$-33.5M
$79.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCEL
RCEL
WTBA
WTBA
Q1 26
$12.9M
Q4 25
$-5.4M
$46.5M
Q3 25
$-5.2M
$11.4M
Q2 25
$-10.2M
$13.5M
Q1 25
$-10.3M
$9.7M
Q4 24
$-8.1M
$39.8M
Q3 24
$-7.2M
$12.9M
Q2 24
$-12.8M
$10.0M
Free Cash Flow
RCEL
RCEL
WTBA
WTBA
Q1 26
$12.4M
Q4 25
$-6.1M
$43.2M
Q3 25
$-6.2M
$10.8M
Q2 25
$-10.8M
$12.8M
Q1 25
$-10.5M
$8.3M
Q4 24
$-9.7M
$13.7M
Q3 24
$-11.0M
$7.0M
Q2 24
$-15.4M
$2.7M
FCF Margin
RCEL
RCEL
WTBA
WTBA
Q1 26
46.0%
Q4 25
-34.7%
178.3%
Q3 25
-36.1%
43.0%
Q2 25
-58.4%
53.6%
Q1 25
-56.9%
35.7%
Q4 24
-52.7%
65.6%
Q3 24
-56.1%
34.2%
Q2 24
-101.6%
14.0%
Capex Intensity
RCEL
RCEL
WTBA
WTBA
Q1 26
1.8%
Q4 25
3.8%
13.7%
Q3 25
5.5%
2.6%
Q2 25
2.8%
3.2%
Q1 25
1.2%
6.5%
Q4 24
8.8%
125.3%
Q3 24
19.2%
29.4%
Q2 24
17.5%
37.1%
Cash Conversion
RCEL
RCEL
WTBA
WTBA
Q1 26
1.22×
Q4 25
6.26×
Q3 25
1.23×
Q2 25
1.70×
Q1 25
1.24×
Q4 24
5.61×
Q3 24
2.17×
Q2 24
1.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons